Megestrol

Active ingredient: Megestrol Acetate

In short: Megestrol acetate oral suspension, USP is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).

LabelPAI Holdings, LLC dba PAI Pharma
Label updatedOct 05, 2026

What is Megestrol used for?

Megestrol acetate oral suspension, USP is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).

âš  Boxed warning (FDA's strongest warning)

Megestrol acetate may cause fetal harm when administered to a pregnant woman. For animal data on fetal effects, (see

PRECAUTIONS: Carcinogenesis, Mutagenesis, Impairment of Fertility: Impairment of Fertility). There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking (receiving) this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.

Megestrol acetate is not intended for prophylactic use to avoid weight loss.

The glucocorticoid activity of megestrol acetate oral suspension has not been fully evaluated. Clinical cases of new onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus, and overt Cushing’s Syndrome have been reported in association with the chronic use of megestrol acetate. In addition, clinical cases of adrenal insufficiency have been observed in patients receiving or being withdrawn from chronic megestrol acetate therapy in the stressed and non-stressed state. Furthermore, adrenocorticotropin (ACTH) stimulation testing has revealedthe frequent occurrence of asymptomatic pituitary-adrenal suppression in patients treated with chronic megestrol acetate therapy. …

Megestrol dosage

The recommended adult initial dosage of megestrol acetate oral suspension, USP is 800 mg/day (20 mL/day). Shake container well before using.

In clinical trials evaluating different dose schedules, daily doses of 400 and 800 mg/day were found to be clinically effective.

Warnings & precautions

Do not take this medicine if: History of hypersensitivity to megestrol acetate or any component of the formulation. Known or suspected pregnancy.

Therapy with megestrol acetate oral suspension for weight loss should only be instituted after treatable causes of weight loss are sought and addressed. These treatable causes include possible malignancies, systemic infections, gastrointestinal disorders affecting absorption, endocrine disease and renal or psychiatric diseases.

Effects on HIV viral replication have not been determined.

Use with caution in patients with a history of thromboembolic disease.

Exacerbation of pre-existing diabetes with increased insulin requirements has been reported in association with the use of megestrol acetate.

Patients using megestrol acetate should receive the following instructions:

This medication is to be used as directed by the physician.

Report any adverse reaction experiences while taking this medication.

Use contraception while taking this medication if you are a woman capable of becoming pregnant.

Notify your physician if you become pregnant while taking this medication.

Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. The effects of zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.

Megestrol acetate may interact with warfarin and increase International Normalized Ratio (INR). Closely monitor INR in patients taking megestrol acetate and warfarin.

Long-term treatment with megestrol acetate may increase the risk of respiratory infections. …

Megestrol side effects

Adverse events which occurred in at least 5% of patients in any arm of the two clinical efficacy trials and the open trial are listed below by treatment group. All patients listed had at least one post baseline visit during the 12 study weeks. These adverse events should be considered by the physician when prescribing megestrol acetate oral suspension.

ADVERSE EVENTS

% of Patients Reporting

Trial 1 (N = 236) | Trail 2 (N=87) | Open Label Trial

Megestrol Acetate mg/day No. of Patients | Placebo 0 N=34 | 100 N=68 | 400 N=69 | 800 N=65 | Placebo 0 N=38 | 800 N=49 | 1200 N=176

Diarrhea | 15 | 13 | 8 | 15 | 8 | 6 | 10

Impotence | 3 | 4 | 6 | 14 | 0 | 4 | 7

Rash | 9 | 9 | 4 | 12 | 3 | 2 | 6

Flatulence | 9 | 0 | 1 | 9 | 3 | 10 | 6

Hypertension | 0 | 0 | 0 | 8 | 0 | 0 | 4

Asthenia | 3 | 2 | 3 | 6 | 8 | 4 | 5

Insomnia | 0 | 3 | 4 | 6 | 0 | 0 | 1

Nausea | 9 | 4 | 0 | 5 | 3 | 4 | 5

Anemia | 6 | 3 | 3 | 5 | 0 | 0 | 0

Fever | 3 | 6 | 4 | 5 | 3 | 2 | 1

Libido Decreased | 3 | 4 | 0 | 5 | 0 | 2 | 1

Dyspepsia | 0 | 0 | 3 | 3 | 5 | 4 | 2

Hyperglycemia | 3 | 0 | 6 | 3 | 0 | 0 | 3

Headache | 6 | 10 | 1 | 3 | 3 | 0 | 3

Pain | 6 | 0 | 0 | 2 | 5 | 6 | 4

Vomiting | 9 | 3 | 0 | 2 | 3 | 6 | 4

Pneumonia | 6 | 2 | 0 | 2 | 3 | 0 | 1

Urinary Frequency | 0 | 0 | 1 | 2 | 5 | 2 | 1

Adverse events which occurred in 1 to 3% of all patients enrolled in the two clinical efficacy trials with at least one follow-up visit during the first 12 weeks of the study are listed below by body system. …

About this medicine

Megestrol acetate oral suspension, USP contains megestrol acetate, a synthetic derivative of the steroid hormone, progesterone. Megestrol acetate is a white, crystalline solid chemically designated as 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate. Solubility at 37°C in water is 2 mcg per mL, solubility in plasma is 24 mcg per mL. Its molecular weight is 384.52.

The chemical formula is C24H32O4 and the structural formula is represented as follows:

megestrol acetate, USP

Megestrol acetate oral suspension is supplied as an oral suspension containing 40 mg of micronized megestrol acetate per mL.

Megestrol acetate oral suspension contains the following inactive ingredients: alcohol (max 0.06% v/v from flavor), artificial lime flavor, citric acid monohydrate, docusate sodium, glycerin, natural and artificial lemon flavor, purified water, sodium benzoate, sodium citrate dihydrate, sucrose and xanthan gum.

Megestrol acetate oral suspension, 40 mg/mL complies with USP Dissolution Test 2.

The clinical efficacy of megestrol acetate oral suspension was assessed in two clinical trials. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 46622697-2c51-44d5-9f1f-e48f8526f132. Read the full official label on DailyMed.

Related medicines

Tirzepatide Methylphenidate Lisdexamfetamine Amphetamine Orlistat Serdexmethylphenidate and Dexmethylphenidate Benzphetamine Phendimetrazine